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Slumen we placed a second, shorter stent in the upper part of the ﬁrst stent. The
Edwards Sapien XT valve mounted on the Novaﬂex delivery system was then
deployed In the dual caval valve approach we implanted a second valve into the vena
cava superior (SVC) as described.
Results: From August 2nd, 2012 to now we treated 6 pts (2 f, 4 m; 5 ICV single, 1
IVC and SVC dual valve) with a FU up to 11 mo. Safety: Periprocedural mortality:
0%; technical success: 100%; VARC 30-day safety endpoint: 0%, valve dysfunction:
0%. Clinical results: 5/6 pts improved by at least 1 NYHA class, in 5/6 pts signs of
right heart congestion decreased, in 2/2 pts with cardiorenal syndromes and terminal
failure renal function improved allowing discontinuation of dialysis. In 6/6 pts hepatic
veins diameters decreased (-34%). Right heart parameters: In msCT measurements
volumes of the anatomical RV decreased (-14,8%), surprisingly, also volumes of the
anatomical RA decreased (-13%). In echo measurements, TAPSE increased from 14,5
to 18,6 cm.
Conclusions: Percutaneous single or dual caval valve implantation with the Edwards
Sapien XT for severe TR is feasible and safe.With all due care at this early stage, this
approach appears to be a new promising interventional tool to improve right heart
hemodynamics and to ameliorate symptoms of right heart failure in advanced stages of
heart failure.
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Background: Transcatheter aortic-valve implantation (TAVI) has rapidly evolved as
an effective treatment alternative for aortic-valve disease. The currently utilized bio-
prostheses are prone functional degeneration. Autologous, stem cell based, tissue-
engineered heart-valves (TEHV) with self-repair capacity have been repeatedly
proposed to overcome these limitations. We summarize our initial experience on
marrow stromal cell based TAVI in an adult sheep model.
Methods: Tri-leaﬂet TEHV generated from synthetic-scaffolds were integrated into
self-expanding Nitinol stents, seeded with autologous marrow-stromal cells. There-
after, in a series of animal experiments, TEHV were transapically delivered into the
descending aorta (n¼3) and the orthotopic aortic-valve position of adult sheep (n¼16)
using different delivery systems including a generic system and the anatomically-
orienting JenaValve transapical TAVI System (JenaValve, Munich/Germany). Follow
up was up to two weeks. Positioning and functionality were assessed by angiography
and echo before the TEHV underwent post-mortem gross examination and histology.
CT scan was used to assess stent positioning.
Results: Transcatheter implantation of TEHV into the descending aorta (n¼3) and
into the orthotopic aortic-valve position (n¼16) was successful in all animals. Fluo-
roscopy and echo conﬁrmed sufﬁcient positioning at the intended delivery site. All
TEHV tolerated the loading-pressure of the systemic-circulation and no acute ruptures
or tears occurred. Animals displayed intact and mobile leaﬂets with an adequate
functionality (mean trans-valvular gradient <10mmHg in all animals). Importantly,
TEHV orthotopically implanted (n¼16) entirely excluded the native aortic leaﬂets and
did not compromise the coronary arteries. Histology was indicative for an early
cellular-remodelling.
Conclusions: We demonstrate transcatheter based TEHV implantation into the aorta
within a one-step intervention. Our data indicate the feasibility to combine the concept
of TEHV and transcatheter delivery representing a key step towards clinical trans-
lation. Long-term functionality proven, a cell based TEHV approach may represent
a next generation heart-valve therapy concept.
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Background: Percutaneous mitral valve repair requires a close understanding of both
ﬂuoroscopy and periprocedural imaging. Real time 3D transesophageal echocardi-
ography is often used for guidance. We report the use of 3D-echocardiography-
ﬂuoroscopy fusion for mitral valve repair.
Methods: Patients presenting to our center for mitral valve repair had their procedure
performed using an echocardiographic-ﬂuoroscopic overlay system. The EchoNavi-
gator (Philips, Inc) system requires transesophageal echocardiography, which is
registered to ﬂuoroscopy based on probe angle and position. Relevant structures can
be marked on echocardiography and tracked with ﬂuoroscopy. Procedural charac-
teristics of these patients were collected.
Results: Nine patients at our center underwent percutaneous mitral valve repair with
MitraClip (Abbott Vascular, Santa Clara, CA) using a novel 3D-echocardiographic-
ﬂuoroscopic overlay technology (EchoNavigator, Philips Inc.). The EchoNavigator
system was useful for transseptal puncture, understanding mitral valve anatomy,
sheath exchange, clip advancement, and post-deployment visualization.B42 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 YConclusions: The use of EchoNavigator echo-ﬂuoroscopy overlay system is feasible
and useful in MitraClip intervention.TCT-132
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Background: We evaluated an alternative method to treat post PTA dissection using
a novel device, The Tack-IT Endovascular System, by Intact Vascular, Wayne, PA,
indicated for tissue apposition to optimize angioplasty results in peripheral arteries.
The Tack is a circumferential, self-expanding Nitinol device 6mm in length. The Tack
is designed to provide focal treatment only where needed. The Tack accommodates
arterial diameters between 2.5 - 5.5mm and has low outward force onto the arterial
wall. Up to 8 Tacks can be used to treat lesions up to 100mm in length.
Methods: One hundred thirty eight subjects were enrolled in the Tack Optimized
Balloon Angioplasty (TOBA) study. The lesion length was <100mm. The primary
endpoints were Safety and Device Technical Success at 30 days. Safety included
major device-related adverse event(s) including device embolization, emergency
surgical revascularization, index limb amputation (above the ankle) or clinically-
driven TLR at 30 days. Device Technical Success was the ability of the Tack to
resolve post-PTA dissection demonstrated that the artery at the Tack(s) location
remained patent at the end of the procedure (<30 % residual stenosis). Subjects were
followed 1, 6 and 12 months.
Results: FULL STUDY RESULTS WILL BE AVAILABLE BY TCT. Ninety one of
the 138 subjects are enrolled. The mean age was 70 with 62% males. The co-
morbidities included 65% with diabetes, 62% smokers, 73% hypertension and 64%
elevated cholesterol. Eighty four (84) subjects had a sub-optimal PTA, 5 optimal PTA
and 2 did not meet the I/E criteria. The mean lesion length was 47.5mm and RVD
5.40mm. At 30 days (primary endpoint) there were no major device-related adverse
events, emergency surgical revascularizations, no index limb amputations. One (1)
clinically-driven TLR (1.2%) reported. One hundred percent (100%) technical success
was achieved in all the treated lesions and all (292) Tacks were successfully placed.
Conclusions: The Tack is designed to create tissue apposition with minimal amount
of metal and low outward force to allow natural arterial ﬂexibility and low neointimal
response. Long term clinical evidence will conﬁrm the clinical beneﬁts of this novel
technology.
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Background: Arterial aneurysms (An) are traditionally treated surgically, but more
and more by interventional procedures with a high technical success rate, but some
problems are not solved like protection of aneurysm rupture, endoleaks, stent
thrombosis, collateral branch thrombosis. We used a new concept of stent, the
Multilayer Flow Modulator (MFM*) to treat An. and try to avoid some drawbacks
encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several inter-
connected layers without any covering. Our earliest in vitro (theorical simulation),
computerized Fluid dynamics, Molecular Modelization and in vivo tests demonstrated
that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying theears of Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013
